Zura Bio Limited (ZURA)
(Delayed Data from NSDQ)
$4.38 USD
+0.23 (5.54%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $4.40 +0.02 (0.46%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Zura Bio Limited falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | NA | NA |
Cost Of Goods | 0 | 0 | 0 | NA | NA |
Gross Profit | 0 | 0 | 0 | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 63 | 3 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -63 | -3 | -1 | 0 | 0 |
Non-Operating Income | 2 | 6 | 8 | NA | NA |
Interest Expense | 0 | 0 | 0 | NA | NA |
Pretax Income | -61 | 4 | 7 | NA | NA |
Income Taxes | 0 | 0 | 0 | NA | NA |
Minority Interest | 9 | 0 | 0 | NA | NA |
Investment Gains/Losses | 0 | 0 | 0 | NA | NA |
Other Income/Charges | 0 | 0 | 0 | NA | NA |
Income From Cont. Operations | -61 | 4 | 7 | NA | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | NA | NA |
Net Income (GAAP) | -69 | 4 | 7 | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -63 | -3 | -1 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | NA | NA |
Income After Depreciation & Amortization | -63 | -3 | -1 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 33.06 | 13.80 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -2.09 | 0.21 | NA | NA | NA |
Diluted Net EPS (GAAP) | -2.09 | 0.21 | 0.61 | NA | NA |
Fiscal Year end for Zura Bio Limited falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 11.76 | 8.38 | 10.83 | 10.19 | 33.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | -11.76 | -8.38 | -10.83 | -10.19 | -33.91 |
Non-Operating Income | 1.43 | 0.63 | 2.35 | 1.92 | -0.12 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -10.33 | -7.75 | -8.47 | -8.27 | -34.03 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 2.34 | -7.02 | -2.20 | 0.00 | 10.88 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -10.33 | -7.75 | -8.47 | -8.27 | -34.03 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -12.67 | -0.73 | -6.28 | -8.27 | -44.90 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 74.95 | 46.92 | NA | 46.88 | 34.30 |
Diluted EPS Before Non-Recurring Items | -0.17 | -0.02 | NA | -0.18 | -1.31 |
Diluted Net EPS (GAAP) | -0.17 | -0.02 | 2.16 | -0.18 | -1.31 |